Nature Clinical Practice Endocrinology & Metabolism
Long-term Effects of Pegvisomant in Patients With Acromegaly CME

Disclosures

Release Date: April 22, 2008; Valid for credit through April 22, 2009
Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians

Contents of This CME Activity
    To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

  1. Long-term Effects of Pegvisomant in Patients With Acromegaly
    Israel Hodish, MD, PhD
    Ariel Barkan, MD

Go to Test Questions

 
Legal Disclaimer
The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Copyright © 2008 Medscape.

 
Medscape
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Describe the objectives of treatment of acromegaly
  2. List therapeutic approaches to the treatment of acromegaly
  3. Identify the benefits of pegvisomant therapy in patients with acromegaly
  4. Describe the adverse effects of pegvisomant used in the treatment of acromegaly
  5. Describe the appropriate dosages of pegvisomant for the treatment of acromegaly
Authors and Disclosures

Israel Hodish, MD, PhD
Disclosure: Israel Hodish, MD, PhD, has disclosed no relevant financial relationships.


Ariel Barkan, MD
Disclosure: Ariel Barkan, MD, has declared that he serves on the speakers' bureau for Tercica and Novartis. Dr. Barkan has received grant or research support from Genentech, Pfizer, and Tercica.


Désirée Lie, MD, MSEd
Disclosure: Désirée Lie, MD, MSEd, has disclosed no relevant financial relationships.


Rachel Ashton
Disclosure: Rachel Ashton has disclosed no relevant financial relationships.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.